By Bhanvi Satija (Reuters) -Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...

Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025.

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...